Immediate Impact
3 from Science/Nature 62 standout
Citing Papers
The present and future of bispecific antibodies for cancer therapy
2024 Standout
Natural killer cell therapies
2024 StandoutNature
Works of Oliver S. Thomas being referenced
Preclinical Assessment of AMG 596, a Bispecific T-cell Engager (BiTE) Immunotherapy Targeting the Tumor-specific Antigen EGFRvIII
2021
A novel BCMA/CD3 bispecific T-cell engager for the treatment of multiple myeloma induces selective lysis in vitro and in vivo
2016
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Oliver S. Thomas | 295 | 464 | 325 | 331 | 27 | 1.0k | |
| Philipp Gödel | 104 | 778 | 409 | 255 | 21 | 1.4k | |
| Michael D. Burdick | 160 | 145 | 226 | 512 | 20 | 966 | |
| Danuta J. Herzyk | 225 | 184 | 677 | 337 | 47 | 1.3k | |
| Henry C. Stevenson | 95 | 237 | 496 | 197 | 30 | 1.1k | |
| H Neda | 143 | 211 | 513 | 754 | 45 | 1.3k | |
| Yun Chen | 60 | 253 | 153 | 438 | 54 | 1.3k | |
| Samuel Litwin | 286 | 537 | 164 | 489 | 31 | 1.4k | |
| Peter Chu | 69 | 221 | 175 | 204 | 36 | 914 | |
| Michelle M. Appenheimer | 43 | 509 | 589 | 435 | 16 | 1.3k | |
| Peter Henriksen | 239 | 203 | 186 | 253 | 42 | 1.3k |
All Works
Login with ORCID to disown or claim papers
Loading papers...